164 related articles for article (PubMed ID: 35143806)
1. Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.
Chen J; Liu J; Xu B; Cao Y; Liang X; Wu F; Shen X; Ma X; Liu J
Toxicol Appl Pharmacol; 2022 Mar; 438():115911. PubMed ID: 35143806
[TBL] [Abstract][Full Text] [Related]
2. Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent.
Yuan W; Su C; Yang X; Li Y; Cao Y; Liang X; Liu J
J Cell Biochem; 2019 Oct; 120(10):16978-16989. PubMed ID: 31111562
[TBL] [Abstract][Full Text] [Related]
3. Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways.
Yang L; Hu Y; Zhou G; Chen Q; Song Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677672
[TBL] [Abstract][Full Text] [Related]
4. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
5. Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity.
Yang A; Li MY; Zhang ZH; Wang JY; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Jin HL; Zuo HX; Ma J; Jin X
J Ethnopharmacol; 2021 Jun; 273():113598. PubMed ID: 33220359
[TBL] [Abstract][Full Text] [Related]
6. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma.
Chai ZT; Kong J; Zhu XD; Zhang YY; Lu L; Zhou JM; Wang LR; Zhang KZ; Zhang QB; Ao JY; Wang M; Wu WZ; Wang L; Tang ZY; Sun HC
PLoS One; 2013; 8(10):e77957. PubMed ID: 24194905
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.
Cheng CC; Chao WT; Shih JH; Lai YS; Hsu YH; Liu YH
Cancer Chemother Pharmacol; 2021 Jul; 88(1):143-153. PubMed ID: 33860837
[TBL] [Abstract][Full Text] [Related]
9. Erianin inhibits the oncogenic properties of hepatocellular carcinoma via inducing DNA damage and aberrant mitosis.
Dong H; Wang M; Chang C; Sun M; Yang F; Li L; Feng M; Zhang L; Li Q; Zhu Y; Qiao Y; Xie T; Chen J
Biochem Pharmacol; 2020 Dec; 182():114266. PubMed ID: 33035506
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
11. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
12. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis.
Su C; Zhang P; Liu J; Cao Y
Biomed Pharmacother; 2017 Apr; 88():521-528. PubMed ID: 28129624
[TBL] [Abstract][Full Text] [Related]
13. Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma.
Jiang H; Wu D; Xu D; Yu H; Zhao Z; Ma D; Jin J
Int J Biol Sci; 2017; 13(6):701-711. PubMed ID: 28655996
[TBL] [Abstract][Full Text] [Related]
14. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
15. Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh‑7 cells by regulating the ERK‑VEGF/MMP9 signaling pathway.
Chen Y; Chen X; Ding X; Wang Y
Mol Med Rep; 2019 Oct; 20(4):3317-3325. PubMed ID: 31432165
[TBL] [Abstract][Full Text] [Related]
16. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
17. The role of the vascular endothelial growth factor/vascular endothelial growth factor receptors axis mediated angiogenesis in curcumin-loaded nanostructured lipid carriers induced human HepG2 cells apoptosis.
Wang F; He Z; Dai W; Li Q; Liu X; Zhang Z; Zhai D; Chen J; Chen W
J Cancer Res Ther; 2015; 11(3):597-605. PubMed ID: 26458588
[TBL] [Abstract][Full Text] [Related]
18. γ-H2AX promotes hepatocellular carcinoma angiogenesis via EGFR/HIF-1α/VEGF pathways under hypoxic condition.
Xiao H; Tong R; Ding C; Lv Z; Du C; Peng C; Cheng S; Xie H; Zhou L; Wu J; Zheng S
Oncotarget; 2015 Feb; 6(4):2180-92. PubMed ID: 25537504
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
20. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
